RxDoctor Payments Data

Colleen Carpenter, APRN

Family · Lincoln, NENPI 1740379791

Payments from drug & device makers

What this record shows

Abbott accounts for 82.5% of it on its own, with 14 other manufacturers making up the rest. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,409in general payments, 2019–2025

Across 98 payments — averaging $55.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$258
  • AstraZeneca$150
  • Novartis$92
  • Scpharmaceuticals Inc.$87
  • Novo Nordisk$72
  • plus $288 from 9 others

What the payments were for

  • Travel & lodging$3,10557%
  • Food & beverage$2,30443%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,409 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$79,883
Medicare patients
532
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan363$403,886
EliquisApixaban366$347,649
FarxigaDapagliflozin Propanediol216$185,566
XareltoRivaroxaban161$158,028
JardianceEmpagliflozin110$97,974
Potassium Chloride831$20,404
Repatha SureclickEvolocumab36$19,497
Torsemide503$14,236
Metoprolol Succinate619$7,539
VascepaIcosapent Ethyl12$4,430
Furosemide795$4,218
Carvedilol453$3,438
Atorvastatin Calcium363$3,270
Spironolactone383$2,871
Nebivolol Hcl36$2,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$92$403,886363 claims
PfizerEliquis$14$347,649366 claims
AstraZenecaFarxiga$150$185,566216 claims
Boehringer IngelheimJardiance$65$97,974110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.

Other family in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →